A.P. Pharma, Inc. Stock OTC Bulletin Board
Equities
APPA
US00202J2033
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- USD | - |
Jun. 12 | Connect Biopharma Names New Chief Executive, Chair | MT |
May. 29 | Heron Therapeutics Submits Prior Approval Supplement to the FDA for Zynrelef Vial Access Needle | MT |
Financials (USD)
Sales 2024 * | 148M | Sales 2025 * | 178M | Capitalization | 515M |
---|---|---|---|---|---|
Net income 2024 * | -14M | Net income 2025 * | 1M | EV / Sales 2024 * | 3.48 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2.9 x |
P/E ratio 2024 * |
-38
x | P/E ratio 2025 * |
513
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.3% |
Latest transcript on A.P. Pharma, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Craig Collard
CEO | Chief Executive Officer | 58 | 23-02-20 |
Ira Duarte
DFI | Director of Finance/CFO | 55 | 23-06-15 |
Chris Storgard
CTO | Chief Tech/Sci/R&D Officer | 58 | 18-10-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Craig Collard
CEO | Chief Executive Officer | 58 | 23-02-20 |
Susan Rodriguez
BRD | Director/Board Member | 60 | 21-09-19 |
Craig Johnson
BRD | Director/Board Member | 62 | 14-01-12 |
1st Jan change | Capi. | |
---|---|---|
+35.39% | 51.07B | |
-7.75% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+11.70% | 26.35B | |
-17.56% | 19.46B | |
+40.92% | 13.58B | |
+29.62% | 12.46B | |
-2.84% | 11.75B |
- Stock Market
- Equities
- HRTX Stock
- APPA Stock